1-β-D-lyxofuranosyl-2H-[1,2,4]triazine-3,5-dione | 54-25-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-β-D-lyxofuranosyl-2H-[1,2,4]triazine-3,5-dione
• 英文别名: 1β-D-Lyoxofuranosyl-6-aza-uracil；2-[(2R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazine-3,5-dione
• CAS: 54-25-1；4719-17-9；6007-09-6；14048-23-8；23624-66-0；26187-77-9；26578-10-9；93060-34-5
• 化学式: C₈H₁₁N₃O₆
• 分子量: 245.192
• InChiKey: WYXSYVWAUAUWLD-QNKHKLGJSA-N

物化性质

• 密度：
  2.08±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.1
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  132
• 氢给体数：
  4
• 氢受体数：
  7

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S22,S36
• 危险类别码：
  R20/21/22
• WGK Germany：
  3
• 海关编码：
  29349990
• RTECS号：
  XY8575000
• 包装等级：
  III
• 危险类别：
  6.1
• 危险性防范说明：
  P280
• 危险品运输编号：
  2811
• 危险性描述：
  H302,H312,H332,H350

文献信息

• Multi-Functional Ionic Liquid Compositions for Overcoming Polymorphism and Imparting Improved Properties for Active Pharmaceutical, Biological, Nutritional, and Energetic Ingredients
  申请人：Rogers Robin D.

  公开号：US20120264605A1

  公开（公告）日：2012-10-18

  Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of use and manufacture.

  本发明涉及离子液体和制备含有活性制药、生物、营养和能量成分的离子液体组合物的方法。同时，本发明还涉及使用所述组合物的方法，以克服多晶性、克服溶解度和输送问题、控制释放速率、增加功能、增强功效（协同作用）和改善使用和制造的便利性。
• [EN] 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS<br/>[FR] PROMÉDICAMENTS DE 6-AZA-NUCLÉOSIDE COMME AGENTS ANTIVIRAUX POUR LE TRAITEMENT D'INFECTIONS VIRALES
  申请人：SOUTHERN RES INST

  公开号：WO2022133323A1

  公开（公告）日：2022-06-23

  The present disclosure is concerned with 6-aza-nucleoside prodrugs that are capable of inhibiting a viral infection and methods of treating viral infections such as, for example, human immunodeficiency virus (HIV), human papillomavirus (HPV), chicken pox, infectious mononucleosis, mumps, measles, rubella, shingles, ebola, viral gastroenteritis, viral hepatitis, viral meningitis, human metapneumovirus, human parainfluenza virus type 1, parainfluenza virus type 2, parainfluenza virus type 3, respiratory syncytial virus, viral pneumonia, yellow fever virus, tick-home encephalitis virus, Chikungunya virus (CHIKV), Venezuelan equine encephalitis (VEEV), Eastern equine encephalitis (EEEV), Western equine encephalitis (WEEV), dengue (DENV), influenza, West Nile virus (WNV), zika (ZIKV), Middle East Respiratory Syndromes (MERS), Severe Acute Respiratory Syndrome (SARS), and coronavirus disease 2019 (COVID-19), using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  本公开涉及能够抑制病毒感染的6-aza-核苷类前药物，以及治疗病毒感染的方法，例如人类免疫缺陷病毒（HIV）、人乳头瘤病毒（HPV）、水痘、传染性单核细胞增多症、腮腺炎、麻疹、风疹、带状疱疹、埃博拉、病毒性胃肠炎、病毒性肝炎、病毒性脑膜炎、人类副流感病毒1型、副流感病毒2型、副流感病毒3型、呼吸道合胞病毒、病毒性肺炎、黄热病病毒、蜱媒乙型脑炎病毒、基孔肯雅病毒（CHIKV）、委内瑞拉马蹄病毒脑炎病毒（VEEV）、东部马脑炎病毒（EEEV）、西部马脑炎病毒（WEEV）、登革热病毒（DENV）、流感、西尼罗河病毒（WNV）、寨卡病毒（ZIKV）、中东呼吸综合症（MERS）、严重急性呼吸综合症（SARS）以及2019冠状病毒病（COVID-19）。本摘要旨在作为特定领域搜索的工具，不限制本发明。
• Nucleoside agents for the reduction of the deleterious activity of extended nucleotide repeat containing genes
  申请人：The Board of Trustees of the Leland Stanford Junior University

  公开号：US10675293B2

  公开（公告）日：2020-06-09

  Aspects of the invention include methods of reducing the deleterious activity of a mutant extended nucleotide repeat (NR) containing target gene in a cell by contacting the cell with an effective amount of a nucleoside agent, as well as compositions used in such methods. The deleterious activity (e.g., toxicity and/or dis-functionality of products encoded thereby) of a mutant extended NR containing target gene may be reduced in a variety of different ways, e.g., by reducing (and in some instances differentially, including selectively, reducing) the production or activity of toxic expression products (e.g., RNA or protein) encoded by the target gene. Kits and compositions for practicing the subject methods are also provided.

  本发明的各个方面包括通过使细胞与有效量的核苷酸制剂接触来降低细胞中含突变延长核苷酸重复（NR）靶基因的有害活性的方法，以及用于这种方法的组合物。含突变延长核苷酸重复（NR）靶基因的有害活性（如毒性和/或其编码产物的功能失调）可以通过多种不同的方式降低，例如，通过减少（在某些情况下，包括选择性地减少）靶基因编码的毒性表达产物（如 RNA 或蛋白质）的产生或活性。还提供了用于实施本课题方法的试剂盒和组合物。
• Modulators of DUX4 for regulation of muscle function
  申请人：GENEA BIOCELLS USA (HOLDINGS), INC.

  公开号：US10933068B2

  公开（公告）日：2021-03-02

  Disclosed herein are methods and compositions for the treatment of facioscapulohumeral muscular dystrophy and other muscle diseases or disorders. In some cases, the methods and compositions involve the use of methyltransferase inhibitors to inhibit or repress DUX4 expression in muscle cells. Further disclosed herein are methods and cell based assays for screening compounds for the treatment of facioscapulohumeral muscular dystrophy and other muscle diseases.

  本文公开了治疗面肱骨肌营养不良症和其他肌肉疾病或紊乱的方法和组合物。在某些情况下，这些方法和组合物涉及使用甲基转移酶抑制剂来抑制或抑制肌肉细胞中 DUX4 的表达。本文进一步公开了用于筛选治疗面阔肌营养不良症和其他肌肉疾病的化合物的方法和基于细胞的检测方法。
• DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION
  申请人：ANGIOTECH INTERNATIONAL AG

  公开号：EP1594459B1

  公开（公告）日：2010-02-17